Promising Data from CARE PMR Study Presented at AAIC 2025 Highlights Portable MRI as a Game-Changer for Point-of-Care Monitoring
New interim results presented by our partner Hyperfine at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto are set to transform Alzheimer’s patient monitoring. Data from the CARE PMR study, led by researchers at the Benzinger Lab at Washington University School of Medicine in St. Louis, shows that the Swoop® AI-powered portable MRI system achieved 100% sensitivity in detecting ARIA-E (amyloid-related imaging abnormalities with edema) in Alzheimer’s patients undergoing Lecanemab therapy.
This groundbreaking finding underscores the potential of ultra-low-field MRI as a triage tool for rapid, point-of-care ARIA screening.
The study, which aligns with FDA-required MRI safety monitoring protocols for amyloid-targeting therapies, demonstrates how portable MRI can significantly
improve monitoring and expand access to care for patients receiving treatments like Lecanemab.
As Hyperfine’s Chief Medical Officer, Dr. Edmond Knopp, stated, “We are proud to collaborate with leading clinicians and researchers who share our vision of advancing Alzheimer’s care through accessible innovation.”
This new era of Alzheimer’s care, with imaging that meets patients where they are, is now within reach.
Want to learn more?
Read the full article
Go back to News & Updates page.
Questions
about integrating this technology?
Contact the UpCare team for more information.